http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Chintharlapalli, Sudhakar,Papineni, Sabitha,Abdelrahim, Maen,Abudayyeh, Ala,Jutooru, Indira,Chadalapaka, Gayathri,Wu, Fei,Mertens-Talcott, Susanne,Vanderlaag, Kathy,Cho, Sung Dae,Smith III, Roger,Safe Wiley Subscription Services, Inc., A Wiley Company 2009 International journal of cancer: Journal internati Vol.125 No.8
<P>Methyl 2-cyano-3,11-dioxo-18β-olean-1,12-dien-30-oate (CDODA-Me) is a synthetic derivative of glycyrrhetinic acid, a triterpenoid phytochemical found in licorice extracts. CDODA-Me inhibited growth of RKO and SW480 colon cancer cells and this was accompanied by decreased expression of Sp1, Sp3 and Sp4 protein and mRNA and several Sp-dependent genes including survivin, vascular endothelial growth factor (VEGF), and VEGF receptor 1 (VEGFR1 or Flt-1). CDODA-Me also induced apoptosis, arrested RKO and SW480 cells at G<SUB>2</SUB>/M, and inhibited tumor growth in athymic nude mice bearing RKO cells as xenografts. CDODA-Me decreased expression of microRNA-27a (miR-27a), and this was accompanied by increased expression of 2 miR-27a-regulated mRNAs, namely ZBTB10 (an Sp repressor) and Myt-1 which catalyzes phosphorylation of cdc2 to inhibit progression of cells through G<SUB>2</SUB>/M. Both CDODA-Me and antisense miR-27a induced comparable responses in RKO and SW480 cells, suggesting that the potent anticarcinogenic activity of CDODA-Me is due to repression of oncogenic miR-27a. © 2009 UICC</P>
Immune checkpoint inhibitors for solid organ transplant recipients: clinical updates
Shun Kawashima,Kole Joachim,Maen Abdelrahim,Ala Abudayyeh,Kenar D. Jhaveri,Naoka Murakami 대한이식학회 2022 Korean Journal of Transplantation Vol.36 No.2
Transplant care continues to advance with increasing clinical experience and improve- ments in immunosuppressive therapy. As the population ages and long-term survival improves, transplant patient care has become more complex due to comorbidities, frailty, and the increased prevalence of cancer posttransplantation. Immune check- point inhibitors (ICIs) have become a standard treatment option for many cancers in non-transplant patients, but the use of ICIs in transplant patients is challenging due to the possibility of disrupting immune tolerance. However, over the past few years, ICIs have gradually started to be used in transplant patients as well. In this study, we review the current use of ICIs after all solid organ transplantation procedures (kidney, liver, heart, and lung). Increasing data suggest that the type and number of immunosuppres- sants may affect the risk of rejection after immunotherapy. Immunotherapy for cancer in transplant patients may be a feasible option for selected patients; however, prospec- tive trials in specific organ transplant recipients are needed.